I re-read the Ann and can take that my question #2 was answered regarding ODD approval date as it was maintained thru annual submission, so instead of RC110 they have applied for RC220. So unless FDA considers RC220 as an bioequivalenf of RC110 how could they transfer the ODD status to RC220 based on historical data? Hence my other questions regarding toxicology report. Can you point me to the answers for my other Q’s? Thanks
I re-read the Ann and can take that my question #2 was answered...
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.80 |
Change
0.085(4.97%) |
Mkt cap ! $311.6M | |||
| Open | High | Low | Value | Volume |
| $1.85 | $1.96 | $1.75 | $710.2K | 383.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3000 | $1.78 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.80 | 3476 | 2 |
View Market Depth
| Last trade - 13.26pm 26/06/2024 (20 minute delay) ? |
| RAC (ASX) Chart |